



CSE: OPTI · OTCQX: OPTHF · FSE: 8BN

INVESTOR PRESENTATION MARCH 2026

The direct-to-clinic pharmaceutical drug manufacturer.

STRICTLY CONFIDENTIAL: This presentation is being furnished on a confidential basis solely for informational purposes about Optimi Health Corp. and may not be reproduced or otherwise distributed, in whole or in part, without prior written consent.

Disclaimer.

This presentation does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the matters or entities described herein. Recipients are responsible for conducting their own investigations and analyses of Optimi and the information contained or referred to herein and should not act solely on the basis of any information contained or referred to in this presentation. No representation or warranty, express or implied, is given and no responsibility or liability is accepted by any person, with respect to the accuracy, fairness or completeness of this presentation or its contents or any oral or written communication in connection with any matter described herein.

This presentation does not constitute and should not be construed as, an advertisement, public offering, prospectus, offering memorandum or an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company in Canada, the United States or any other jurisdiction. No securities commission or similar authority has reviewed or in any way passed upon this presentation, and any representation to the contrary is an offence. Any offer to sell or solicitation of an offer to buy securities will be made only by means of a prospectus that meets the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Forward-looking.

This presentation contains forward-looking statements that relate to Optimi's current expectations and views of future events. Statements that express or involve discussions as to expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct.

Market data and certain industry data and forecasts included in this presentation were obtained from internal company surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. Optimi has not independently verified any of the data from third-party sources. This presentation is confidential and is being provided solely for your information; by accepting it, you agree to keep it confidential and not to use it for any purpose other than to evaluate a potential investment in Optimi.

Offering summary.

Follow-on equity offering and initial Nasdaq listing.

ISSUER	Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF)	SHARES OUT (PRE)	3,233,333 shares**
PROPOSED LISTING	NASDAQ: OPTH	SHARES OUT (POST)	5,108,333 – 5,733,333; 5,389,583 – 6,108,333 (full over-allotment)**
OFFERING TYPE	Follow-On Offering; Initial Listing on Nasdaq	USE OF PROCEEDS	Commercial business development and product distribution; general working capital
SECURITIES OFFERED	Common Stock	LOCKUP	180 days
OFFERING PRICE	\$6.00 – \$8.00 per share	EXPECTED PRICING	March 2026
OFFERING SIZE	2,142,857 shares of common stock, excl. 15% over-allotment option*	SOLE BOOK-RUNNING MANAGER	Joseph Gunnar & Co., LLC

* Based on pricing at midpoint of range. ** Calculated using a proposed 1:30 reverse stock split.

Use of proceeds.

Allocation for proposed **USD \$15.0M** offering.

Underwriting discounts & offering-related expenses	\$1.3M
	—
Scaling production & distribution in current markets	\$3.5M
	25.5%
Market entry — Israel, United States & sales growth	\$2.2M
	16%
General working capital & operating expenses	\$8.0M
	58.5%
Total	\$15.0M · 100%

Amounts represent approximate allocation based on midpoint pricing. Actual allocation may vary.

Supplying patients today.

Positioned to take advantage of the rescheduling revolution shaping the market of tomorrow.

SNAPSHOT · 11 MAR 2026

Share Price

US\$0.22

Shares Out

96.8M

Market Cap

US\$22M

HQ

Vancouver, BC

01 Early-Mover Advantage Optimi's GMP-compliant MDMA and psilocybin products are already reaching patients under Australia's Authorized Prescriber Scheme.	02 Real-World Evidence Patient-reported outcomes are being collected across both products, creating an extensive clinical data set.	03 Global Rescheduling With legally-permitted MDMA and psilocybin under active review worldwide, Optimi is positioned to supply new markets as they open.	04 Vertically Integrated GMP Purpose-built, Health Canada-licensed facilities ensure compliance and scalable production for any future market.	05 Commercial Today While others remain in costly, multi-year trials, Optimi is commercial today — building sales channels and market share.
---	--	--	---	---

A chronic, costly unmet need.

Legacy options — SSRIs, benzos, psychotherapy — reflect limited efficacy and high relapse.

28.3M

US ADULTS WITH DEPRESSION

≈ 8.3% of the adult population; 8.7M have treatment-resistant depression.

\$232B

US ANNUAL PTSD BURDEN (2018)

≈ \$19,630 per person with the condition.

\$540B

PROJECTED DEPRESSION COST / YR BY 2030

Healthcare (\$127.3B), presenteeism (\$43.3B), absenteeism (\$38.4B).



Australia

PTSD: **1,000,000**

TRD: **300,000**

TAM: **1,300,000 patients**



United States

PTSD: **12,300,000**

TRD: **8,700,000**

TAM: **30,000,000 patients**

CONTRIBUTING FACTORS Modern lifestyle pressures, digital and social media overload, increasing loneliness and social isolation, socioeconomic pressures, and AI-driven labor displacement.

“Australian psychiatrists are now prescribing Optimi's GMP-compliant MDMA and psilocybin capsules for therapeutic use. Having two regulated psychedelic drug products reaching clinics and patients is a significant milestone for the company and the industry.”



JJ Wilson
CHAIRMAN



MDMA.



Global MDMA access is accelerating. Optimi is actively supplying patients in Australia, Canada, and Israel — with hundreds treated to date.

WHAT IS MDMA?

- Psychoactive compound that enhances emotional processing, reduces fear responses, and strengthens therapeutic connection.
- Clinically studied primarily for PTSD, with applications to depression, anxiety, and addiction.
- Recognized by the FDA as a Breakthrough Therapy for PTSD.

OPTIMI'S MDMA

- Formulated in two dosage formats for regulated medical programs and clinical trials worldwide.
- Australian clinics have been prescribing Optimi's MDMA since October 2024.



Psilocybin.



Optimi's proprietary natural psilocybin extract capsule is already reaching patients in Australia.

WHAT IS PSILOCYBIN?

- Naturally occurring psychedelic compound found in certain fungi, known for inducing neuroplasticity and resetting dysfunctional brain activity.
- Clinically studied for treatment-resistant depression, MDD, and other mental health conditions.
- Recognized by regulators as having therapeutic potential; programs expanding in Australia, Canada, and Israel.

OPTIMI'S PSILOCYBIN

- Standardized for consistent dosing meeting global pharmaceutical drug standards.
- Australian clinics began prescribing Optimi's psilocybin in September 2025.



The direct-to-clinic model.

As with ketamine and cannabis, the global MDMA & psilocybin market will emerge through rescheduling — driven by cost-efficient medicine, GMP manufacturing, and scalable direct-to-clinic distribution.

 AUSTRALIA PLAYBOOK

Q2 2023	TGA formally reschedules MDMA & psilocybin; Authorised Prescribers Scheme launches.
Q1 2024	First patients treated in Australia.
Q3 2024	Optimi MDMA sales begin to Australian clinics.
Q3 2025	Optimi psilocybin sales begin to Australian clinics.
Q4 2025	Dept. of Veterans' Affairs approves funding for MDMA and psilocybin with psychotherapy.
Q1 2026	Continued commercialization and clinic sales.

 US PLAYBOOK

The US rescheduling journey could follow Australia's, with Optimi's strategy combining its proven playbook and learnings from J&J's Spravato ketamine commercialization or cannabis rescheduling in the US.

KETAMINE CASE STUDY

In the US, J&J's Spravato has scaled rapidly — 6,800+ certified clinics, 46,000+ monthly prescriptions, and annual sales exceeding **\$1B**, growing 50%+ YoY. Generic ketamine remains widely used in parallel — a dual-track market where branded and non-branded products both achieve adoption.

Global rescheduling is underway.

Optimi is well positioned to supply jurisdictions that open a regulated framework.

MDMA

- Australia, Canada, Switzerland, and Israel allow MDMA therapy via Special Access Programs for PTSD.
- The Netherlands has formed a State Commission to explore MDMA medical use and rescheduling.
- The US FDA granted Breakthrough Therapy designation and is evaluating NDAs, setting up a potential rescheduling pathway.

PSILOCYBIN

- Australia, Canada, Switzerland, and Denmark allow psilocybin access under Special Access (or equivalent) programs.
- Germany launched the EU's first compassionate-use program permitting psilocybin for treatment-resistant depression.
- In June 2024, New Zealand began granting approvals to prescribe psilocybin.
- The Czech Republic formally rescheduled psilocybin on January 1, 2026.

Before & after.

Rescheduling is a government classification that determines whether a drug has an accepted medical use. As a GMP manufacturer, Optimi is positioned to supply any new market.

BEFORE RESCHEDULING · SCHEDULE I

Restricted.

- No accepted medical use
- Illegal outside tightly controlled clinical trials
- No prescription access for physicians
- No reimbursement from insurers
- No pharmacy or hospital distribution

AFTER RESCHEDULING · SCHEDULE II / III

Unlocked.

- Accepted medical use recognized by government
- Licensed physicians prescribe in regulated settings, covered by insurers
- Incorporated into standardized treatment guidelines, driving velocity
- Distributed via pharmacies, hospitals, and clinics
- Unlocks broad access across multiple indications

Subject to applicable regulatory requirements and market conditions. U.S. Controlled Substances Act, 21 U.S.C. § 812.

“Everybody in my agency — and over at [Secretary Doug Collins's] agency — is very anxious to get a rule out there that will allow these kinds of studies and will allow access under therapeutic settings. We're working through that process now.”

“I think that we're going to get it done.”



Robert F. Kennedy Jr.

SECRETARY · US DEPARTMENT OF HEALTH AND HUMAN SERVICES

The US is warming up.

The Trump administration has shown significant interest in accelerating psychedelic-assisted therapy.

2020s	Increasing legislative and advocacy efforts (federal and state) to enable therapeutic use or rescheduling of psilocybin. In 2024, ten state bills were introduced across AK, AZ, CA, HI, IL, IN, MD, MA, NJ, and WI.
Jul 2025	FDA Chief calls the evaluation of MDMA and other psychedelics "a top priority," with a new program to expedite drugs that serve "the health interests of Americans" — slashing review time from six months to as little as one month.
Aug 2025	US DEA officially requests HHS loosen the federal restriction on psilocybin from Schedule I to II under the Controlled Substances Act.
On rescheduling	Optimi deploys the same distribution strategy as Australia — establishing itself as the reliable, proven supplier of choice to future US clinics.

“This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months.”

HEALTH SECRETARY ROBERT F. KENNEDY JR. TO MEMBERS OF CONGRESS · JULY 2025

The Optimi operational flywheel.

Nearly 5,000 total doses shipped globally as of Q1 2026;
repeat orders scaling with distribution partners in Australia;
capacity to manufacture millions of doses for export.



~5,000

TOTAL DOSES SHIPPED GLOBALLY · Q1 2026

DVA

AUSTRALIAN DEPT. OF VETERANS' AFFAIRS NOW REIMBURSING VETERANS

Psychedelic Assisted Psychotherapy (PAP)
using MDMA or psilocybin for eligible DVA clients.

Global patient opportunity.



Australia is the proof-of-concept market. The United States — once rescheduled — represents a step-change in addressable demand roughly 23× larger in combined PTSD and TRD populations.

Sources: Phoenix Australia, NIMH, WHO World Mental Health Survey, Zhdanova M. et al. — J. Clin. Psychiatry (2021).

The only one with drugs in market.

Psychedelic company market caps and current drugs in-market — January 2026.

	Optimi	Resilience	atai	Definium	Compass	Helus
MARKET CAP ¹	\$22M	N/A	\$1.6B	\$1.9B	\$829M	\$287M
MDMA IN MARKET	✓	×	×	×	×	×
PSILOCYBIN IN MARKET	✓	×	×	×	×	×
INSURANCE REIMBURSEMENT	✓	×	×	×	×	×
DRUG ESTABLISHMENT LICENSE (HEALTH CANADA)	✓	×	×	×	×	×

1) FactSet data as of Mar 11, 2026. 2) Estimated from available public filings.

The team.

Executives, directors, and strategic advisors who built and scaled global consumer and pharmaceutical brands.

DS

Dane Stevens
CEO, CMO & DIRECTOR

JW

JJ Wilson
CHAIRMAN

BS

Bryan Safarik
COO & DIRECTOR

JS

Jacob Safarik
INTERIM CFO & DIRECTOR

PC

Dr. Preston Chase
CHIEF SCIENTIFIC OFFICER

JM

Jason Mosberian
INDEPENDENT DIRECTOR

KL

Karina Lahnakoski
DIR. QUALITY & COMMERCIAL

STRATEGIC ADVISORS

CW

Chip Wilson
FOUNDER · LULULEMON (NASDAQ: LULU) & AMER SPORTS (NYSE: AS)

Serial entrepreneur who built a \$50B+ global athletic apparel brand.

HP

Harley Pasternak
CELEBRITY FITNESS TRAINER · NYT BEST-SELLING AUTHOR

Nutritionist; Master's in Exercise Physiology, University of Toronto.

Why Optimi.

The trusted manufacturer of choice for emerging psychedelic-based mental health treatments.

01

Licensed to export MDMA & psilocybin

Drug Establishment License from Health Canada to export psychedelic finished drug products for any allowable indication.

03

Growing \$12B global market

MDMA and psilocybin have growing clinical evidence for use in the \$12B global anxiety disorders treatment market.

05

US rescheduling opportunity

With patients now using MDMA and psilocybin in Special Access Programs, countries including the US are moving toward rescheduling.

02

Available now in Australia

Optimi's MDMA and psilocybin are actively being exported for use in qualified clinics, with licensed entities conducting clinical trials globally.

04

Cost-effective on-site GMP

Facilities ready to scale production with new market opportunities.


06

Early mover advantage

Competition is focused on clinical development; Optimi is focused on establishing sales channels and increasing market share.

The facility.

Health Canada-licensed. GMP-compliant. Purpose-built for MDMA and psilocybin at scale.



optimi

CSE: OPTI · OTCQX: OPTHF · FRA: 8BN

THANK YOU

**The direct to clinic
pharmaceutical drug
manufacturer.**

INVESTOR RELATIONS

Lucas A. Zimmerman

MZ Group · MZ North America

+1 (262) 357-2918

OPTHF@mzgroup.us

ONLINE

optimihealth.ca